evitria AG

Service provider for recombinant antibody expression in CHO cells.
From sequence to antibody | 4 weeks | expressed in CHO

[evitria AG @evitria_ag]

PEGS Europe 2024 is just around the corner! 🚀 Join us in exploring the latest advancements in protein and antibody engineering. Don’t miss the chance to discuss your therapeutic projects with our team—let’s collaborate to push the boundaries of innovation. See you in Barcelona!

[evitria AG @evitria_ag]

⚙️ Developing bispecific antibodies involves optimizing binding, assembly, immunogenicity, and production. With the right expertise, these challenges can be managed effectively.

At Evitria, we support your development with expert solutions. Learn more: https://t.co/KlUfVYKaX9

[evitria AG @evitria_ag]

Attending PEGS Europe 2024? Visit Evitria to explore our advances in therapeutic and bispecific antibody production.

📅 November 5-7, 2024
📍 Barcelona, Spain

Connect with us at our booth or schedule a meeting. See you in Barcelona!

[evitria AG @evitria_ag]

Discover how bispecific antibodies are used in therapy and their future potential.🧫 Desmond Schofield explores their current and upcoming applications in his latest article.

Read more: https://t.co/WleYIB1VOR

[evitria AG @evitria_ag]

🔬 New article: 'Types of Bispecific Antibodies: Exploring Formats in Therapeutic Development.' Discover various formats and their therapeutic applications.

Read more: https://t.co/V0edTSNYco

[evitria AG @evitria_ag]

Only 2 days left until the Festival of Biologics in Basel!
We’re excited to showcase the latest in immunotherapy, antibodies, and biosimilars.” Visit us at booth #900 to discuss how evitria’s expertise can support your projects. Looking forward to connecting and innovating! ⭐

[evitria AG @evitria_ag]

🚀 Proud to contribute to the conversation on bispecific antibodies (bsAbs) @BioScience_PK🧬

Read the full article "Creating Bispecific Antibodies: Giving No Chance to Chance" here: https://t.co/pSkB5ocWCB

#BispecificAntibodies #Biotech #CancerResearch

[evitria AG @evitria_ag]

Bispecific antibodies 🦠 (bsAbs) target two diseases at once, offering more effective treatments and driving therapeutic innovation.

See how evitria supports bsAb R&D in our article: https://t.co/9EEh5jnXDE

[evitria AG @evitria_ag]

In our bispecific antibody series, we've covered formats like Crossmab, Duobody, and techniques like Knobs-into-Holes and Electrostatic Steering.

At evitria, we support your bispecific antibody R&D. Contact us for expert guidance and take your research further. 🔬

[evitria AG @evitria_ag]

Attending the Festival of Biologics in Basel? Meet evitria at booth #900 to discuss the latest in immunotherapy, antibodies, and more!

📅 Oct 15-17, 2024
📍 Basel, Switzerland

Let’s drive innovation in biologics together! 🦾

[evitria AG @evitria_ag]

🌐✨ Industry insight! Discover our latest article, What Companies Are Developing Bispecific Antibodies. We spotlight key players revolutionizing treatments for severe diseases.

🚀 Curious about the innovators? Read the full article: https://t.co/EeJSfhiG6x

[evitria AG @evitria_ag]

Electrostatic Steering enhances the formation and stability of bispecific antibodies, improving binding specificity for targeted therapies.🧬

At evitria, we use this technique to optimize bispecific antibodies for your research.

[evitria AG @evitria_ag]

📈 Check out the 2024 21st Annual Biopharma Manufacturing Report!
Highlights:
- Insights from 220 companies and 179 suppliers
- Analysis of trends, capacity, and growth
- Expert commentary on key issues

📚 Access the report here: https://t.co/WkmfXlLT7B

[evitria AG @evitria_ag]

Check out our article, "FDA Approved Bispecific Antibodies," reviewing FDA-approved bispecific antibodies from the past decade and their impact on treatment. Learn more: https://t.co/jjLwRT1c5i

[evitria AG @evitria_ag]

Knobs-into-Holes technology enhances bispecific antibody development by preventing homodimerization, ensuring specificity and stability. Despite requiring specialized purification, KIH improves antibody purity. At evitria, we apply KIH to optimize bispecific antibody projects.

[evitria AG @evitria_ag]

🔍 Choosing the right bispecific antibody format is crucial. With many options and distinct advantages, understanding the key factors can greatly impact your research and outcomes.

Explore what to consider in our latest article: https://t.co/cTgJcGU673

[evitria AG @evitria_ag]

IgG-scFv combines the stability of IgG with the flexibility of scFvs for versatile therapeutic use. 🧬
The Key Points are:
-Enhanced stability and specificity
-Purity may require SEC
-No IP restrictions offering project flexibility.
What challenges have you faced?
#Antibodies

[evitria AG @evitria_ag]

New insight: Understanding bispecific antibody side effects
Explore potential side effects of these powerful therapeutics and how they influence treatment strategies. Stay informed on bsAb safety! 🔬

Read more: https://t.co/H7joCproGq

[evitria AG @evitria_ag]

🔍 New article alert! Discover the basics of bispecific antibodies in our latest piece.
We offer a clear overview of their mechanism of action and expression.
Curious about how these innovative antibodies work? 🦠
learn more: https://t.co/leUZkqL45y

[evitria AG @evitria_ag]

Introducing Genmab's Duobody system: an innovative bispecific antibody format for precise targeting of two antigens. It simplifies production and boosts stability.🧫

#Duobody #BispecificAntibodies #Genmab #evitria #Research